HER2/neu 655 A > G polymorphism is associated with higher cardiotoxicity but not with less efficacy of trastuzumab, in HER2-positive breast cancer patients

dc.conference.date	SEP 19-OCT 18, 2020
dc.conference.title	ESMO Virtual Congress
dc.contributor.author	Blancas, I.
dc.contributor.author	Rodriguez-Serrano, F.
dc.contributor.authoraffiliation	[Blancas, I.] Hosp Clin San Cecilio, Oncol, Granada, Spain
dc.contributor.authoraffiliation	[Rodriguez-Serrano, F.] Univ Granada, Inst Biopathol & Regenerat Med, Granada, Spain
dc.date.accessioned	2025-01-07T13:59:02Z
dc.date.available	2025-01-07T13:59:02Z
dc.date.issued	2020-09-01
dc.identifier.doi	10.1016/j.annonc.2020.08.300
dc.identifier.essn	1569-8041
dc.identifier.issn	0923-7534
dc.identifier.unpaywallURL	http://www.annalsofoncology.org/article/S0923753420402960/pdf
dc.identifier.uri	https://hdl.handle.net/10668/26021
dc.identifier.wosID	573469100178
dc.issue.number	4
dc.journal.title	Annals of oncology
dc.journal.titleabbreviation	Ann. oncol.
dc.language.iso	en
dc.organization	SAS - Hospital Universitario San Cecilio
dc.organization	SAS - Hospital Universitario San Cecilio
dc.page.number	S314-S314
dc.publisher	Elsevier
dc.rights.accessRights	open access
dc.title	HER2/neu 655 A > G polymorphism is associated with higher cardiotoxicity but not with less efficacy of trastuzumab, in HER2-positive breast cancer patients
dc.type	conference output
dc.type.hasVersion	VoR
dc.volume.number	31
dc.wostype	Meeting Abstract

Collections